This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Belantamab mafodotin parenteral

Updated 2 Feb 2023 | Belantamab mafodotin


Infusions of belantamab mafodotin.

Drugs List

  • belantamab mafodotin 100mg powder for concentrate for soln for infusion vial
  • BLENREP 100mg powder for concentrate for soln for infusion vial
  • Therapeutic Indications


    Multiple myeloma - refractory

    Monotherapy for the treatment of multiple myeloma in adults patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, who have demonstrated disease progression on the last therapy.



    2.5mg/kg once every 3 weeks.

    Additional Dosage Information

    Dose modifications for adverse reactions

    Corneal adverse reactions
    Mild (Mild superficial keratopathy, Decline from baseline of 1 line on Snellen Visual Acuity): Continue treatment at current dose
    Moderate (Moderate superficial keratopathy, Decline from baseline of 2 or 3 lines (and Snellen Visual Acuity not worse than 20/200)): Withhold treatment until improvement to mild severity or better. Consider resuming treatment at a reduced dose of 1.9mg/kg.
    Severe (Severe superficial keratopathy, Decline from baseline of more than 3 lines): Withhold treatment until improvement to mild severity or better. For worsening symptoms that are unresponsive to management, consider discontinuing treatment.

    Other adverse reactions

    Grade 2-3 (Platelet count 25,000 to less than 75,000/microlitres): Consider withholding and/or reducing the dose to 1.9mg/kg.
    Grade 4 (Platelet count less than 25,000/microlitres): Withhold until platelet count improves to Grade 3 or better. Consider resuming at reduced dose of 1.9mg/kg.

    Infusion-related reactions
    Grade 2 (moderate): Interrupt infusion and provide supportive treatment. Once symptoms have resolved, resume at lower infusion rate by at least 50%.
    Grade 3 or 4 (severe): Interrupt infusion and provide supportive treatment. Once symptoms have resolved, resume at lower infusion rate by at least 50%. If anaphylactic or life-threatening infusion reaction occurs, permanently discontinue and provide appropriate emergency care.


    For intravenous infusion only.


    Children under 18 years
    Weight above 130kg
    Weight below 40kg
    Moderate hepatic impairment
    Severe renal impairment

    Precautions and Warnings

    Dry eyes
    Severe thrombocytopenia

    Advise ability to drive/operate machinery may be affected by side effects
    Give pre-treatment counselling and consideration of oocyte cryopreservation
    Give pre-treatment counselling and consideration of sperm cryopreservation
    Premedicate all patients with prior infusion related reactions
    Treatment to be initiated and supervised by a specialist
    Contains polysorbate
    Advise patient to administer PF artificial tears 4 times a day
    Consult local policy on the safe use of anti-cancer drugs
    Record name and batch number of administered product
    Staff: Not to be handled by pregnant staff
    Exclude pregnancy prior to initiation of treatment
    Monitor full blood count regularly
    Monitor ophthalmic function
    Consider discontinuing treatment/dose modification if keratopathy occurs
    Consider withholding/reducing dose if grade 2 thrombocytopenia occurs
    Discontinue / interrupt treatment if ulcerative keratitis develops
    Interrupt/reduce infusion rate by 50% if grade 2 infusion reaction occurs
    Discontinue if anaphylactoid reaction occurs
    Discontinue permanently if life threatening infusion reactions occur
    Interrupt treatment if severe infusion reaction occurs
    Suspend treatment and/or reduce dose if grade 4 thrombocytopenia
    May cause impaired fertility
    Female: Contraception required during and for 4 months after treatment
    Male: Contraception required during and for 6 months after treatment
    Breastfeeding: Do not breastfeed during & for 3 months after treatment
    Contact lenses should not be worn during treatment

    Ophthalmic examination should be performed by an eye care specialist at baseline, before the subsequent 3 treatment cycles and as clinically indicated during treatment.

    Pregnancy and Lactation


    Belantamab mafodotin is contraindicated during pregnancy.

    The manufacturer recommends that belantamab mafodotin should not be used during pregnancy unless the benefit to the mother outweighs the potential risk to the foetus. There are no data from the use of belantamab mafodotin in pregnant women. Based on the mechanism of action of the cytotoxic component, belantamab mafodotin can cause embryo-foetal harm. Human immunoglobulin G (IgG) is also known to cross the placenta, therefore there is the potential for belantamab mafodotin to be transmitted from the mother to the foetus.


    Belantamab mafodotin is contraindicated during breastfeeding.

    The manufacturer recommends that women should be advised to discontinue breastfeeding prior to initiating treatment with belantamab mafodotin and for 3 months after the last dose. It is not known whether belantamab mafodotin is excreted into human breast milk. Immunoglobulin G (IgG) is present in breast milk in small amounts, so based on the mechanism of action belantamab mafodotin may cause serious adverse reactions in breastfed infants.

    Side Effects

    Aspartate aminotransferase increased
    Blurred vision
    Creatine phosphokinase increased
    Dry eyes
    Eye irritation
    Eye pruritus
    Gamma glutamyl transferase (GGT) increased
    Impaired vision
    Infective keratitis
    Infusion related reaction
    Ocular discomfort
    Reduced visual acuity
    Ulcerative keratitis
    Upper respiratory tract infection


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: August 2021

    Reference Sources

    Summary of Product Characteristics: Blenrep 100 mg powder for concentrate for solution for infusion. GlaxoSmithKline UK. Revised January 2021.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.